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INTRODUCTION	
Breast Cancer 
Epidemiology 
Incidence 
Breast cancer is the most common neoplasia in women worldwide. One woman out of eight in the 
United States will develop breast cancer during her life1. In Italy, in 2018, about 52,800 new cases 
were diagnosed2. 
Mortality 
Breast cancer is not only the most common malignancy in women, but also the leading cause of death 
by cancer. It represents the 29% of the causes of oncological death before the age of 50, 21% between 
50 and 69 years and 14% after 70 years2. 
Survival 
In Italy the relative survival, is 87% at 5 years and 80% at 10 years. The 5-year survival difference 
between age groups is relatively limited: 91% in women between 15 and 44 years, 92% between 45 
and 54 years, 91% between 55 and 64, 89% between 65 and 74 years, 79% in women over 75 years 
old2. 
Geographical variability 
The incidence of breast cancer presents a wide national and international variability, with a non-
homogeneous distribution worldwide, maybe due to inhomogeneity of risk factors and diagnostic 
modalities3.  
 5 
Risk Factors 
The literature concerning breast cancer risk factors is still debated about the understanding of the 
underlying biological mechanisms. Furthermore in many cases breast cancer do not have specific and 
therefore potentially predictable risk factors4. 
The best known are: 
AGE: The risk of developing breast cancer progressively increases with age, reaching a peak around 
50 years; starting from this age it continues to grow even if more slowly. The probability of 
developing breast cancer within the age of 49 is 2.4% (1 out of 42 women), 5.5% between 50 and 69 
(1 out of 18 women) and 4.7% among 70 and 84 years (1 woman out of 21). This trend seems to be 
due to the continuous endocrine-proliferative stimulus that the mammary gland receives, combined 
with the progressive damage to the DNA and to the accumulation of epigenetic alterations that modify 
the expression of oncogenes and tumor suppressor genes. 
SEX: The vast majority (99-99.5%) of breast cancer affects women. Male breast cancer is rare5. 
FAMILIARITY AND INHERITANCE: Most breast cancers are sporadic. A woman with a family of 
first degree positive for breast cancer has a doubled chance of developing breast cancer6. Only in 7-8% 
of cases the tumor is defined as hereditary3. The mainly involved genes are BRCA1 and BRCA2 
(genes with autosomal dominant transmission), which are normally responsible for DNA repair7, 8. 
These genes are also associated with ovarian cancer. Other high penetrance genes associated with 
breast cancer are TP53, PTEN CHD1, STK1113. Then there are intermediate penetrance genes, such 
as CHEK2, ATM, PALB214, which represent 2-3% of breast cancer cases. Today the research 
activities are focus on the role of Single Nucleotide Polymorphisms (SNPs)9. 
MENSTRUAL AND REPRODUCTIVE FACTORS: The larger the fertility window, the higher the 
probability of developing breast cancer. In this sense a late menarche and an early menopause had a 
protective effect10, 11. Nulliparity, a first full-term pregnancy in late age and failure to breastfeed carry 
an increased risk11. In particular, the relative risk of breast cancer is reduced by 7% for each full-term 
pregnancy and 4.3% for each year of breastfeeding. 
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HORMONAL FACTORS: The higher the levels of circulating estrogen and the longer the glandular 
epithelium of the breast is exposed, the greater the risk of developing breast cancer3. The literature of 
the last 20 years on the association between hormone replacement therapy (HRT) and breast cancer is 
very extensive and articulated18-14. Users of hormonal contraceptives have a mild increase in the 
likelihood of illness compared to non-users, this risk returns to be equal to that of non-users about 10 
years after the suspension13.  
DIETARY AND METABOLIC FACTORS: A high consumption of animal fats and alcohol seem to 
be associated with the development of breast cancer3. Obesity and the metabolic syndrome are a 
recognized risk factor, probably linked to the excessive presence of adipose tissue, the main source of 
estrogen in menopause15. Protective role is instead played by physical education16. 
RADIATION EXPOSURE: Women who have been exposed to radiation therapy in the thoracic 
district, especially if at a young age, have a higher frequency of breast cancer17. The risk of disease 
increases in proportion to the amount of radiation received and the earliness of the exposure18. 
PRECANCEROUS LESIONS: A condition of epithelial hyperplasia without atypia is associated with 
a 1.5 to 2 times greater risk of developing a carcinoma. In atypical ductal hyperplasia and in atypical 
lobular hyperplasia this risk becomes 4-5 times greater. Atypical hyperplasia, in fact, is a clonal 
proliferation with the same histological features of carcinoma in situ, but smaller or equal in size to 
2mm. 
Natural History 
The origin of breast cancer is a clone of cells with multiple genetic aberrations, which cause a defect 
in the mechanisms of proliferation, differentiation and apoptosis. The acquisition of these mutations is 
conditioned by the inheritance of susceptibility genes or by environmental factors. Most carcinomas 
arise in terminal duct lobular units (TDLU). Subsequently they produce tumors that differ in 
morphology and biological behavior. The role of the tumor microenvironment in progression disease 
is now widely recognized19,20. The distinction between carcinoma in situ and invasive carcinoma is 
fundamental. 
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We must also consider the metastatic diffusion, both by lymphatic or hematogenous pathways. Among 
the lymph node groups that may be affected in case of breast cancer we find the axillary lymph nodes, 
the supraclavicular lymph nodes and the lymph nodes along the internal mammary chain. 
Breast cancer tends to metastasize to bones, lungs, central nervous system and liver. In the 1970s, 
Bernard Fisher defined breast cancer as a systemic disease21. 
 
Diagnosis 
Mammography and Tomosynthesis 
Mammography is nowadays the gold standard for the breast evaluation, both in symptomatic and 
asymptomatic women22–24. 
The types of isolated or variously associated anomalies searched are: nodular lesions, architectural 
distortions and calcifications. Mammography is the only technique able to recognize 
microcalcifications and distortions of the mammary architecture, these type of lesions can represent 
the only "spy" of an asymptomatic tumor. Sensitivity increases with the increase of the adipose 
component: if under the age of 50 it does not exceed 83%, in women over fifty it exceeds 98% 25. In 
dense breasts sensitivity is reduced up to 70% and in these cases it can be very useful to integrate with 
ultrasound26 analysis. 
Tomosynthesis is a new method, which produces images of organ sections. It therefore allows an 
increase in diagnostic sensitivity and specificity compared to mammoghaphy27. 
Breast Ultrasound 
Ultrasonography is generally used in association with mammography, causing an increase in 
sensitivity on both palpable and non-palpable lesions, especially in the presence of dense breasts. 
Instead, it represents the gold standard technique for young women under 35 years28, 29. 
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Breast ultrasound allows the differentiation of cystic from solid nodules, analyzing the content of 
cysts, assessing the presence of axillary lymph nodes. Last but not least, offers the possibility of 
ultrasound-guided biopsies for pathological diagnosis both on breast and lymph node.  
Magnetic resonance (MRI) 
Magnetic resonance has gained an increasingly important role in recent years both for diagnosis and 
for loco-regional staging of breast cancer30. 
The applications of magnetic resonance are: define the exact extension of the tumor in case of 
discrepancy between mammography and ultrasound, identify a multifocality or a multicentricity, 
lobular histological type, identify periprosthetic nodules, evalue the efficacy of neoadjuvant 
chemotherapy, management of occult carcinoma of the breast; it can finally be used as a screening test 
in high risk patients of breast cancer (carriers of BRCA1 or BRCA2 mutations or of women with a 
strong family positivity) 31. Its routine use is still much debated today. In particular, too high cost and 
too many false positives are attributed to MRI 32,33. 
 
Cytology and Histology 
The diagnosis of certainty of breast cancer can be reach only with cytological and / or histological 
sampling. The difference between the two procedures is given by the quantity of tissue that is taken34,5. 
A recent needle biopsy method, but now widely established in clinical practice is the Core Needle 
Biopsy (CNB); it involves the taking of a small frustule of tissue from the suspect area. The degree of 
reliability of the method exceeds 96% 36. 
The Vacuum-Assisted Breast Biopsy (VABB), better known by the name of the device used to 
perform it, the Mammotome, allows the collection of tissue samples from very small lesions through a 
sterile probe. This method is indicated for radiologically dubious or suspected mammary 
microcalcifications and for the evaluation of small parenchymal distortions, nodules or opacity37.  
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Histological classification, grading and staging 
Histological classification 
The classification of breast bening or malignant neoplasm that is used today is the one of the World 
Health Organization of 2012 (Table 1). 
Malignant lesions of the breast are generally differentiated between epithelial tumors and non 
epithelial tumors, starting from the surrounding stroma. Malignant epithelial tumors can be 
distinguished from anatomo-pathological point of view in carcinomas in situ and invasive 
carcinomas38. 
The “non-special type infiltrating carcinoma” (NST) represents the majority of invasive forms (from 
44 to 75%)3. Invasive lobular carcinoma is at second place by frequency (about 15%) 39. It is 
characterized by the proliferation of small, poorly cohesive cells arranged in a fibrous stroma. This 
variant generally is difficult to be identified at screening mammography because it tends to be 
camouflaged in the glandular parenchyma, often multifocal or multicentric and bilateral (20-40%)39–43. 
Other special types occur less frequently38,44. 
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Table 1. Invasive breast carcinomas (without microinvasive carcinoma and invasive papillary lesions)  
Grading 
The histological grading of an invasive carcinoma is important to determine the characteristics of 
breast cancer and its prognosis45. Several schemes have been proposed for the gradation of neoplasms, 
but the one most frequently used is the scheme proposed by Elston and Ellis46: 
• Grade 1: well differentiated tumor; 
• Grade 2: discretly differentiated tumor; 
• Grade 3: poorly differentiated tumor. 
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Staging 
Staging of breast cancer is initially clinical, formulated on the basis of physical examination and 
radiological examinations, and subsequently histopathological. Staging is essentially based on three 
parameters: tumor size (T), number of regional lymph nodes involved (N) and distant metastases (M).  
In addition to the clinical examination to complete the evaluation of the T parameter is essential to 
carry out a bilateral mammography and an ultrasound of the breast; in selected cases it may be useful 
to use a nuclear magnetic resonance (see above). The N parameter (evaluation of regional lymph 
nodes) is done by an axillary ultrasound and, in case of doubt, a needle aspiration citology. Finally, to 
evalue the M parameter (distant metastases) the mostly used tests are47: 
Chest X-ray: to highlight the presence of metastatic lung lesions 
Abdominal ultrasound: exclude the presence of metastases in the liver and for the evaluation of the 
genital apparatus; 
Bone scintigraphy: to detect bone metastases48; 
Laboratory analisis: some are part of the normal preoperative routine, others are useful for staging. In 
this second category we find the tumor markers CA 15-3, CEA, CA12549-50. 
 
Molecular classification 
The immunohistochemical analysis performed on the specimen allows an evaluation of the expression 
of: 
Hormonal receptors: estrogen receptors (ER), and progesterone receptors (PgR). 
Ki67: nuclear protein encoded by the MKI67 gene. It is used to estimate the growth fraction of the 
neoplasm. 
HER2: receptor tyrosine kinase responsible for the control of cell growth, survival and proliferation. 
Its activation therefore promotes tumor growth.  
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According to the San Gallen Consensus Conference of 2013 breast cancers can be divided into five 
molecular subtypes according to the receptor status and the gene expression profile. Each subtype is 
characterized by a specific prognosis and response to therapy: 
Luminal A (40-55%): usually associated with a better prognosis. These tumors express hormone 
receptors, but not HER2. These tumors express ER, PgR> 20% and Ki67 <20% 51, generally well-
differentiated, with a low proliferative index and strongly responsive to hormonotherapy. 
Luminal B HER2-negative (6-10%): although they express ER, these carcinomas express PgR <20% 
or Ki67> 20%, less differentiated; they may benefit from chemotherapy as well as hormone therapy. 
Luminal B HER2-positive (15-20%): positive hormone receptors, over expressing HER2, regardless 
of the proliferation index, medium-high grading; they also benefit from monoclonal antibody therapy. 
HER2-positive (non-luminal, 7-12%): over-express HER2, but do not express hormone receptors, 
generally poorly differentiated, highly proliferating and high risk of metastasis. 
Triple negative (13-25%): do not express either hormone receptors or HER2. They generally have a 
high proliferative index (> 50%), a good response to chemotherapy. 
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Therapy 
Breast cancer treatment is multidisciplinary. Only the cooperation between each member of the core-
team is foundamental to plan the correct and personalized strategy for the patients. 
 
Surgical Therapy 
Conservative	breast	surgery	(lumpectomy)	
Lumpectomy is a surgical technique which allow to remove the cancer and some normal tissue around 
it, but not the breast itself guaranteeing a radical oncology and a natural respect for cosmetics. Its 
oncological legitimacy has been demonstrated; included in a multidisciplinary treatment, it guarantees 
survival rates identical to mastectomy52. 
The indications are extended to all the cases in which the relations between the diameter of the 
neoplastic lesion and the breast volume allows an oncologically correct resection and a good aesthetic 
result. It is not recommended in case of multicentricity, the impossibility to perform adjuvant 
radiotherapy and previous radiotherapy or a state of pregnancy in the first or second trimester.  
Radiotherapy is to be considered complementary to conservative surgery and necessary for a complete 
loco-regional control of the disease53. 
In the last decade, conservative surgery has undergone further evolution with the oncoplastic 
technique. Oncoplastic surgery is a new surgical technique combining oncological radicalism with the 
use of plastic surgery for remodeling and rebuilding the breast54-56.  
Mastectomy	
Mastectomy is the complete removal of the mammary gland, which can be performed with different 
techniques. 
Halsted radical mastectomy involves the removal of the mammary gland with a large portion of skin 
including the nipple-areola complex, large and small pectoral muscles, and axillary lymph nodes of I, 
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II and III level57. Nowadays it is performed only in very rare and selected cases of massive muscular 
infiltration by the neoplasia. 
In the radical mastectomy modified according to Patey, the gland and skin are removed with only the 
small pectoral muscle and the axillary lymph nodes up to the II or III level. 
The Madden-modified radical mastectomy differs from the latter in saving both pectoral muscles. 
Simple mastectomy involves the removal of gland and skin without an axillary dissection. 
In recent years it has become increasingly widespread the so-called "conservative" mastectomy 
technique58. They guarantee surgical radicality and a better reconstructive aesthetic result. 
Axillary	lymph	node	treatment	
The study of axillary lymph nodes has a therapeutic and prognostic utility. Lymph node status strongly 
affects the prognosis of breast cancer patients59. The axillary lymphadenectomy of I, II and III level is 
currently the standard treatment in the presence of metastatic lymph nodes. 
The gold standard surgical technique for invasive breast cancer with non metastatic lymph nodes is the 
sentinel node technique (LNS). The sentinel node is defined as the first lymph node that receives 
lymph directly from the bed of the primary neoplasia60,61. The diameter of the sentinel lymph node 
metastasis influences the possible involvement of the other axillary lymph nodes: in the presence of 
isolated tumor cells (ITC) or micrometastasis (<0.2 cm) axillary dissection is avoided, as it has no 
impact on prognosis62. Furthermore, clinical studies are currently on going concerning the actual need 
for axillary lymphadenectomy in the case of macrometastases, the results of which will be available in 
the near future63–65. Different substances and techniques can be used to identify the sentinel node; the 
use of a radiometabolic tracer (albumin macromolecules with 99mTc) is the most widespread 
technique. 
The removal of a single lymph node avoids acute and chronic complications compared to 
lymphadenectomy such as: pain, paresthesia, lymphoceles, lymphedema, functional impotence of the 
omolateral upper limb66. 
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Radiotherapy 
The association between surgery and radiotherapy is the gold standard in conservative treatment of 
invasive breast cancer to eliminate any residual tumor cells after surgery. Indeed, radiotherapy after 
conservative surgery strongly impacts the risk of local recurrence67,68.The irradiation of the chest wall, 
after mastectomy, is indicated for pT3 and pT4 tumors, in the case of at least 4 positive axillary lymph 
nodes or extracapsular lymph node diffusion68,69. Radiation therapy involves the administration of 
50.0-50.4 Gy with a conventional fractionation (1.8-2 Gy / day, in 5 fractions per week) on the 
residual breast parenchyma or on the chest wall, followed by an overdose (boost) on the operating bed 
(10-16 Gy) 70,71. 
Radiation therapy can lead to acute toxicity (asthenia, skin erythema, epidemiolysis) or late (hardening 
and retraction of the breast, cutaneous dystrophy, telangiectasia, lymphedema of the arm) 72,73. 
 
Medical Therapy 
The adjuvant pharmacological approach of breast breast cancer is very complex. The therapy for each 
patient is personalized and must be taken after a multidisciplinary evaluation. 
Hormonal	therapy:	
Hormonal therapy may be used for patients with hormone-responsive breast cancer (ie with ER 
expression ≥ 1% or PgR ≥ 1%) 74. This tumors (Luminal A and B) are the most frequent form in all 
age groups, particularly in older women75. The side effects of these drugs include sudden hot flushes, 
fluid retention and mood changes; less frequently can be observed thromboembolic phenomena or an 
increased incidence of endometrial tumor76. 
Chemotherapy:	
Chemotherapy treatment can be neoadjuvant or adjuvant. Neoadjuvant chemotherapy precedes 
surgery. It is generally used in the case of locally advanced carcinoma (Locally Advanced Breast 
Cancer, LABC). The primary objectives of neoadjuvant chemotherapy are: obtain a downstaging of 
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the neoplasia and control distant micrometastases through an early "sterilization" of the whole 
organism. The treatment aims to achieve a complete response, the only event related to improving the 
patient's prognosis. 
Adjuvant chemotherapy, on the other hand, aims to reduce the risk of loco-regional recurrence. 
Generally, a drug association (polychemotherapy) is used for 6 months74. The most widely used drugs 
are anthracyclines and taxanes. 
In case of metastatic disease, is generally more appropriate to proceed immediately with chemotherapy 
and to rely on surgical therapy only in selected cases when a full remission of the lesion is obtained for 
at least 6-12 months with permanence of the primitive carcinoma. 
Among the toxicities related to cytotoxic chemotherapy particularly important is leuko-neutropenia 
and chemo-induced amenorrhea (CIA) 76,77. 
Target	therpy:	
More than 20% of breast carcinomas express the HER2 protein78. Although this characteristic is 
generally associated with an unfavorable immunohistochemical characteristics it has a further specific 
therapeutical perspective represented by trastuzumab: monoclonal antibody drug able to act selectively 
on HER2 receptors79-81. 
 
Prognosis 
The prognosis of breast cancer depends on the biological profile of the tumor and on the stage of the 
disease. The information necessary for an accurate prognostic evaluation comes from the 
immunohistochemical profile of the neoplasia. The presence of inflammatory carcinoma and distant 
metastases have a high impact on survival and consequently on prognosis82,83.  
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The factors that have the greatest impact on the risk of recurrence and death are84: 
• Age (<35 years): Under the age of 35, breast cancer has a higher risk of relapse and a reduced 
overall survival85,86 
• Distinction between infiltrating and in situ carcinoma: Carcinoma in situ, by definition, has 
no metastatic potential. The mortality in the 20 years following the diagnosis is 3.3%. The risk 
of developing an infiltrating recurrence in the same breast within the next 20 years is 6.2%87. 
• Status of axillary lymph nodes: In the absence of distant metastases, it represents the most 
important variable for prognosis evaluation. For non metastatic lymph nodes the disease-free 
survival at 10 years is about 70-80%; for 1-3 positive lymph nodes the index drops to 35-40% 
and 10-15% in the presence of more than 10 positive lymph nodes88. 
• Histological subtype: Special histotype carcinomas, such as tubular, mucinous, medullary and 
papillary carcinomas have a more favorable outcome than non-special invasive carcinoma 
(NST) 44,89. 
• ER: Estrogen receptors are expressed in 75-80% of breast cancers. Even low levels of ER 
expression may allow a response to hormone therapy (≥1%) 90. However, there is a direct 
correlation between the level of expression and the level of response91. 
• PgR: Progesterone receptors are expressed in 60-70% of cases. Their expression is positively 
influenced by the expression of ER92. The percentage of expression affects the response to 
endocrinotherapy with an independent impact on overall survival93. 
• HER2: Expressed by 20-30% of tumors. HER2 overexpression represents at the same time a 
consolidated negative prognostic factor and a positive predictor of a response to Trastuzumab 
therapy78–80. 
• Ki67: Estimates the growth of the neoplasia. Although the Ki67 expression cut-off is still 
under discussion it represents an independent factor to determine the prognosis of breast 
cancer51,94. 
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• Histological grade: A G3 neoplasm (poorly differentiated) has a worse prognosis than a G1 
neoplasm (well differentiated)95. 
• Lymphovascular invasion: Defined as the presence of tumor cells inside endothelial cells 
belonging to blood or lymphatic vessels of the breast. Many studies in the literature observe an 
association between lymphovascular invasion, increasing of local recurrence risk and reducing 
of overall survival 96.  
• Multifocality / multicentricity: Multifocality and multicentricity are correlated with the 
presence of lymph node metastasis, causing a reduction in disease-free survival (DFS) and in 
overall survival (OS) 97–99. 
• Margins status: The role of surgical resection margins is still widely discussed in the 
literature. An involvement of the margins by the tumor represents a risk factor for recurrence.  
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Homologous Recombination Deficency (HRD) in Breast Cancer 
 
DNA repair pathways represent a tightly controlled network protecting cells from exogenous and 
endogenous DNA damage. These pathways are frequently aberrant in cancer cells, leading to the 
accumulation of DNA damage and genomic instability. BRCA1 and BRCA2 genes are the most 
known and are associated with hereditary breast and ovarian cancer; they play an important role in the 
process of DNA repair.  
This highly conserved pathway is involved in double-strand DNA break repair by the process of 
homologous recombination (HR). The base excision repair pathway is a second highly conserved 
repair process involved in single-strand DNA breaks. Poly (ADP-ribose) polymerase (PARP) enzymes 
play an important role in this pathway. 
PARP is important for resolving stalled replication forks, and its inhibition during base excision repair 
requires BRCA-dependent HR to resolve100,101. Targeting DNA damage response pathways has 
emerged as an attractive strategy to destabilize tumor genomic integrity and trigger genomic 
catastrophe and cell death in a tumor-specific fashion. 
The role of BRCA1/BRCA2 in double-strand DNA repair via HR has been well documented102, and 
there is mounting evidence that breast cancers arising in BRCA1/BRCA2 germline mutation carriers 
respond favorably to therapies that target DNA repair pathways, such as platinum salts and PARP 
inhibitors (PARPis)103-105. 
Some sporadic breast cancers also harbor defects involving the HR pathway and respond similarly to 
platinum salts. It is also hypothesized that some sporadic breast cancers with defects in the HR 
pathway may benefit from the addition of PARPis to standard therapies106. These sporadic breast 
tumors are commonly referred to as being BRCA-like and are often associated with TNBC. It is 
estimated that up to 40%107of familial and sporadic breast cancers are HR deficient (HRD). 
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Current research has focused on the development of a companion diagnostic to identify sporadic 
BRCA-like tumors that would allow clinicians to identify those patients who may benefit from drugs 
targeting DNA repair pathways and to spare those who are unlikely to benefit. 
Tests of HRD focus on either the detection of the underlying driver mutations responsible for the HR 
defect or the resultant mutational landscape of deficient HR inferred by nonspecific collateral damage 
to the genome Fig. 1. 
 
Driver germline (inherited) or somatic (acquired) mutations may take the form of sequence or 
structural variants that generally result in loss of function or aberrant functioning of BRCA1/ BRCA2 
or other genes encoding members of the HR pathway. 
 
TESTS	OF	DRIVER	MUTATIONS	
Sequence variants (or mutations) include substitutions, deletions, or insertions of nucleotides, 1 kb 
(Fig 1A). Those that occur within genes may result in pathogenic protein abnormalities. The genes and 
their protein products involved in HR are numerous, and their interactions are complex. 
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Germline Mutations in HR-Associated Genes 
In addition to germline BRCA1/BRCA2 mutations, clinical genetic testing panels now include a 
number of proposed breast cancer predisposition genes, although not all of these genes have 
definitively been shown to increase breast cancer risk. Other hereditary predisposition genes involved 
in HR that are proven to be moderate to high risk include PALB2, ATM, and CHEK2. More recently, 
BARD1 and RAD51D have been shown to increase breast cancer risk, whereas some genes (NBN, 
MRE11A, RAD50, RAD51C, BRIP1) are unlikely or confirmed not to increase breast cancer risk108. 
It is not clear if breast cancers arising from these germline mutations are as sensitive to DNA-
damaging therapies as BRCA1/BRCA2-mutated breast cancers109. 
 
Somatic Mutations in HR Genes 
Somatic mutations may also arise in genes involved in HR. Somatic mutations in BRCA1/ BRCA2 
occur in approximately 2.5% of all sporadic breast cancers110. It is hypothesized that somatic 
BRCA1/BRCA2-mutated breast cancers will respond similarly to DNA-damaging therapies, but it is 
not definitively known if germline and somatic BRCA1/BRCA2 mutations are biologically equivalent. 
Next-generation sequencing studies110-113continue to expand the list of genes involved in breast cancer, 
and this list includes HR genes. The extent to which these HR genes drive tumor genesis continues to 
be explored. 
Looking beyond germline BRCA1/BRCA2 mutations has implications in terms of choosing patients 
who will benefit from DNA-damaging therapies, most notably PARPis. How this can be achieved is 
not certain. It is possible that HRD status will be a better predictor of PARPi response in breast cancer.  
 
Copy Number Aberrations 
Copy number aberration/alteration (CNA) refers to acquired changes in copy number of genes in 
tissue, such as tumor, whereas copy number variant (CNV) refers to changes in copy number of genes 
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in the germline, affecting all cells in an individual. CNVs may also be reported in cancer, although 
they are usually qualified with the term acquired as compared with constitutional, so as to differentiate 
between the somatic and germline settings. In contrast to entire chromosome number gains or losses, 
CNA/CNVs are on a much smaller, generally submicroscopic, scale, with the size of DNA copy-
number alterations (gain or loss) being >1 kb in length (Fig1C). Although the extent to which CNAs 
contribute to tumorigenesis is not entirely known, some of the well-established driver events in cancer 
are CNAs (eg, Myc, HER2, Cyclin D1). Furthermore, an increased burden of CNAs is associated with 
higher genomic instability and subsequent malignant transformation114. 
 
Structural Rearrangements 
Inversions, translocations, and recombination change the location or orientation of a DNA sequence115. 
Translocations result in the exchange of DNA between non homologous regions of DNA. Inversions 
result in the change of orientation of a segment of DNA. Recombination results in exchange of DNA 
between homologous regions of DNA, and this structural rearrangement may lead to loss of 
heterozygosity (LOH), a gross chromosomal event that results in the loss of entire genes (eg, BRCA1, 
BRCA2). Two types of acquired LOH are important to note: deletion LOH, where there is a copy 
number loss; and copy number–neutral LOH, where the absolute copy number remains the same (Fig 
1D). Both deletion and copy number–neutral LOH, as with CNAs, lead to allelic imbalance that can be 
inferred by studying single-nucleotide common variation across the genome (single-nucleotide 
polymorphism [SNP] analysis); this may be in the form of other types of DNA microarrays that may 
be fully or partially based on SNP probes across the genome. 
Three tests of structural rearrangements have come to the forefront: telomeric allelic imbalance (TAI), 
large-scale transition (LST), and LOH. 
TAI was developed using a SNP genotype array platform116 to detect the number of chromosomal 
regions with allelic imbalance extending to the subtelomere, a common genomic abnormality that 
leads to an unequal contribution of maternal and paternal DNA sequence but does not necessarily 
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change overall DNA copy number. Break points of TAI regions were nonrandom and enriched for 
CNVs, which results in an imbalance and then leads to HRD, which may result in platinum sensitivity 
in the way that BRCA1 associated cancer responds. Allelic imbalance was the best predictor of 
cisplatin sensitivity after identifying associations between a variety of subchromosomal abnormalities 
and cisplatin sensitivity. 
LST measures chromosomal breaks between adjacent chromosomal regions of at least 10 Mb. 
LOH measures the number of LOH regions > 15 Mb and less than a whole chromosome and was 
recognized as a discriminatory assay in two independent data sets of ovarian tumors117. A composite 
index of all three markers called the homologous recombination deficiency (HRD) assay was 
developed which has been shown to have better sensitivity than the individual scores in predicting HR 
deficiency118. 
While Triple Negative Breast Cancer (TNBC) is heterogeneous, a significant portion of TNBC is 
characterized by defective homologous recombination (HR)109,119. Homologous recombination is a 
high-fidelity DNA repair mechanism that is critical for efficient repair of double-strand DNA breaks. 
While this is a sentient feature of BRCA1/2 mutated breast cancer, defects in HR are common in a 
larger group of TNBCs as well. While Germline BRCA1 and BRCA2 mutations are present in 
approximately 14–20% of TNBCs, a significantly larger percentage of patients have been reported to 
harbor HR defects109,120.  
Clinical identification of HR deficiency at the time of diagnosis is currently being actively investigated 
for its potential to guide optimal therapy selection in TNBC patients. 
Although the primary focus is on TNBC, the role of HRD in many other tumor types is emerging as an 
important target. BRCA1 and BRCA2 mutations are the archetype of HR-deficient tumors and have 
provided insight into other causes of HRD. Developing a reliable biomarker will be the key to 
identifying patients with HRD tumors who may benefit from HRD-targeted therapies. 
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In contrast to genomic tests that characterize the mutations in HR pathway genes or characterize the 
mutational landscapes of HRD tumors, functional measures of HR pathway deficiency provide the 
most direct evidence of an HR pathway defect. 
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Breast	Cancer	Genes	
Family linkage studies have identified high-penetrance genes, BRCA1, BRCA2, PTEN and TP53, that 
are responsible for inherited syndromes. Moreover, a combination of family-based and population-
based approaches indicated that genes involved in DNA repair, such as CHEK2, ATM, BRIP1 
(FANCJ), PALB2 (FANCN) and RAD51C (FANCO), are associated with moderate BC risk. 
Breast cancer predisposition today can be attributed to several levels of genetic susceptibility: rare 
high-risk alleles, conferring a risk more than five and up to 20 times as high as the risk among the 
general population; rare moderate-risk alleles with a relative risk greater than 1.5 and lower than 5, 
and common low-risk alleles conferring risks between 1.01 and 1.5 of the general population. 
Whereas high-risk genes may be identified by traditional linkage analysis of genetic markers in BC 
families, discovering moderate and low risk BC genes requires a different approach. 
Most of these variants occur with high frequency and they have a significant impact on the BC risk. 
 
High-risk	inherited	syndrome	genes	
Hereditary breast and ovarian cancer syndrome (HBOC) is a highly penetrant autosomal dominant 
disorder. It is caused by an inherited germline mutation in cancer susceptibility genes, BRCA1 or 
BRCA2. BRCA1 was cloned in 1994 following a long search for the gene using linkage analysis and 
maps on chromosome 17q21121. This was closely followed by discovery of BRCA2 on chromosome 
13q12–13 in 1995122. They are both classic tumour suppressor genes, which are involved in the 
maintenance of genomic stability by facilitating DNA repair, primarily executing DNA double-strand 
break repair by homologous recombination (HR). Despite of BRCA1 and BRCA2 initially appearing 
to be genes with similar functions, it is now clear that these two genes are different in terms of their 
molecular biology, protein interactions and the cancer risks they confer123. BRCA1 associates with 
multiple repair proteins and cell cycle regulators, being capable of forming multiple protein complexes 
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which contribute to its role in maintaining chromosome stability and tumour suppression124. BRCA1 is 
a substrate of the central DNA damage response kinases ATM (ataxia telangiectasia mutated) and 
ATR (ataxia telangiectasia and Rad3-related protein) that control the DNA damage response. BRCA1 
is required for homology directed repair, a pathway that facilitates error free repair of double-strand 
breaks (DSBs) and resolution of stalled DNA replication forks through HR, as well as post-replicative 
repair in response to UV damage. BRCA1 also regulates the transcription of several genes in cancer 
including ATM125, and homeostasis of itself so that levels remain capable of maintaining genome 
integrity in response to genotoxic insult126. BRCA2 primary function is in HR and it is based upon its 
ability to bind to the strand invasion recombinase RAD51. BRCA2 contains eight BRCT repeats, each 
of which can bind and recruit RAD51 to sites of DNA damage. BRCA2 also interacts with PALB2, 
through which it localizes to DSBs together with BRCA1127. 
BRCA1 and BRCA2 are involved in maintaining genome integrity, at least in part, by engaging in 
DNA repair, cell cycle checkpoint control and even the regulation of key mitotic or cell division steps. 
Thus, the complete loss of function of either protein leads to a dramatic increase in genomic 
instability.  
The estimated BRCA1 and BRCA2 mutation carrier frequencies in the general population are between 
1 in 300 and 1 in 800128. 
TP53 was first identified in 1979 and it is now the most common altered gene in solid tumours. P53 is 
essential in cell-cycle control, resulting in either a delay in cell-cycle progression or apoptosis. 
Inherited germline mutations are rare. However, they are known to result in Li-Fraumeni syndrome 
(LFS). LFS causes childhood tumours: soft tissue, osteosarcomas, gliomas, adrenocortical carcinoma, 
and very early onset BC. Over 70% of classical LFS families inherited TP53 mutations. LFS only 
accounts for less than 0.1% of BC, but mutations in TP53 confer an 18- to 60-fold increased risk of 
BC under the age of 45 years old compared to the general population129. 
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Moderate	breast	cancer	risk	alleles	
CHEK2 
Germline CHEK2 (checkpoint kinase 2) sequence variants have been reported in families with LFS 
that do not carry TP53 mutations130. CHEK2 encodes a cell cycle checkpoint kinase implicated in 
DNA repair. CHEK2 emerged from the sequencing of plausible candidate genes in families with 
multiple cases of BC families without BRCA1/2 mutations131. Its association with increased BC risk 
has been explored in many studies since 2002, and nowadays, its significance has been demonstrated 
with a high statistical degree. 
A particular germline mutation, CHEK2 1100delC, has been associated with a two-fold to three-fold 
increase in BC risk. Many large studies have reported this finding. In 2008, a meta-analysis of studies 
assessing CHEK2 risk in populations of northern and eastern European descendent, calculated odds 
ratios for BC in unselected populations, early-onset BC, and familial BC. For early-onset BC, the 
study estimated an OR of 2.6 (95% CI 1.3–5.5) and also found that for patients selected from a 
population with familial BC, CHEK2 1100delC heterozygotes had a much higher OR 4.8 (95% CI 
3.3–7.2). CHEK2 mutation carriers either with a strong family history of BC or a history of bilateral 
disease was found to be at comparable risk to BRCA carriers with an estimated lifetime risk of 37% 
and 59% respectively. 
These results suggest that CHEK2 1100delC screening should be considered in patients with a strong 
family history of BC. 
 
ATM 
Biallelic mutations in Ataxia telangiectasia mutated (ATM) gene cause the autosomal recessive 
disease Ataxia-telangiectasia (AT). This is a neurodegenerative disorder that is characterized by 
cerebellar ataxia, telangiectases, immunodeficiency, hypersensitivity to ionizing radiation and 
approximately 100 times increased risk of cancer132. ATM is a protein kinase involved in the response 
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to DSBs in a pathway that includes TP53, BRCA1 and CHEK2. DSBs activate ATM, which in turns, 
activates the full DNA damage response133. Heterozygous ATM mutation carriers, found in 
approximately 0.5–1.4% of the general population, do not display the symptoms observed in patients. 
However, several studies have shown an increased risk of cancer in them: tumours of breast, pancreas, 
stomach, bladder, ovary, and chronic lymphocytic leukaemia134. 
Extensive research has been carried out into the association of ATM mutations and BC, showing that 
up to 13% of BC may be due to heterozygous ATM mutations135. The relative risk of BC in 
heterozygous ATM female carriers has been estimated in 2.37% (95% CI, 1.51–3.78) of the general 
population136. Moreover, it has been described that ATM mutations are more frequent in BC patients 
selected on the basis of a family history of BC than from those compared to unselected patients137. 
 
MRN (MRE11–RAD50–NBS1) COMPLEX 
The MRN complex is composed of three proteins, MRE11, RAD50 and NBS1. It binds to damaged 
DNA, undergoes a series of conformational changes to activate and increase ATM affinity for its 
substrates, and retains active ATM at sites of DSBs. MRN complex plays a key role in DNA damage 
detection and activation of the ATM kinase138. 
Mutations in all three members of the MRN complex have been noted in human cancers. Mutations of 
MRE11, NBS1 and RAD50 manifest as ataxia telangiectasia-like disorder (ATL), Nijmegen breakage 
syndrome (NBS) and NBS-like disorder, respectively. Unsurprisingly, carriers of MRE11, NBS1 and 
RAD50 mutations have been implicated in BC.  
Screening for mutations in all the three MRN genes in Finnish population discovered a founder 
mutation in RAD50 associated with a 4.3-fold increase in BC predisposition (OR 4.3, 95% CI 1.5–
12.5)139. However, this mutation has not yet been found in any other populations, including other 
Nordic states, making difficult the confirmation of this association. 
 
 29 
FANC FAMILY 
Fanconi anaemia (FA) is a genetic disease characterized by progressive aplastic anemia, multiple 
congenital defects, and susceptibility to both hematologic and solid malignancies. A defect in any of 
the proteins along the FA pathway prevents cells from repairing interstrand crosslinks and predisposes 
them to chromosomal breakage and cell death. The relationship between FA and BC susceptibility did 
not become fully apparent until it was discovered that BRCA2 and FANCD1 were two different 
names for the same gene. Constitutional inactivating mutations in genes responsible for FA have been 
clearly associated with an increased susceptibility to both BC and OC140 and include the genes BRCA2 
(FANCD1), FANCN (PALB2) and FANCJ (BRIP1). One third of patients homozygous for a FA gene 
mutation will develop cancer by the age of 40 years old. These included squamous cancer of the head 
and neck, meduloblastomas, oesophageal and skin cancers, gynecological cancers, as well as liver and 
kidney tumours141. Strong associations exist between heterozygous mutations of BRCA2/FANCD1 
and breast and/or ovarian cancer development, as described in BRCA1/BRCA2 families. However, 
heterozygous mutations in other FA genes have also been shown to be associated with an increased 
risk of BC. Evidence that other FA pathway related proteins were also BC susceptibility genes did not 
unfold until BRIP1 was identified in FANC-J patients142. FANCJ, also known as BACH1 or BRIP1, is 
a BRCA1-associated DEAH helicase involved in translesion synthesis helping the polymerase bypass 
the interstrand crosslink, placing its role distal to the monoubiquitinated FANCD2 of the FA pathway. 
BRCA1–FANCJ interaction is essential for promoting error-free repair, checkpoint control and for 
limiting DNA damage tolerance143. The most common germline FANCJ/BRIP1 mutant allele is found 
both in BC and FA patients. In 2006, truncating mutations in BRIP1 were identified in BC families. 
Segregation analysis assessed a Relative Risk (RR) of BC of 2.0 (95% CI 1.2–3.2), that increased to 
3.5 (95% CI 1.9–5.7) for carriers younger than 50 years old144. The discovery of another BC 
predisposition gene in the FA pathway PALB2 or FANCN145, suggests that proteins acting 
downstream of monoubiquitinated FANCD2 and FANCI increase the risk of BC, while those acting 
upstream do not146. The role of PALB2 in homologous repair is to behave as a protein that functionally 
bridges BRCA1 and BRCA2 and also cooperates with RAD51 to stimulate recombination147. Biallelic 
PALB2 mutations have been described as responsible for FA subtype FANCN. Research on BC 
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families without BRCA1/2 mutations resulted in identifying PALB2 mutations. However the PALB2 
mutations rarity makes accurate estimation of its penetrance more difficult. A familial-based case-
control association study of PALB2 showed that a monoallelic mutation confers an OR of 2.3 (95% CI 
1.4–3.9) for BC148. As with BRCA2 heterozygotes, PALB2 mutations have been associated with an 
increased risk of pancreatic cancer149. 
 
RAD51 FAMILY 
The RAD51 family consists of several proteins, which preferentially bind to single-stranded DNA, and 
form complexes with each other. RAD51 unwinds duplex DNA and forms helical nucleoprotein 
filaments at the site of a DNA break150. BRCA2 stimulates RAD51-dependent strand exchange151. 
RAD51C was discovered to be the cause of a Fanconi-like disorder152 and is a new cancer 
susceptibility gene153. Six clearly pathogenic mutations were found among 1,100 breast/ovarian cancer 
families. The mutations were found exclusively within 480 pedigrees with the occurrence of both 
breast and ovarian tumors and not in 620 pedigrees with breast cancer only or in 2,912 healthy 
controls. This is a distinctive behaviour from the situation observed with monoallelic mutations in the 
FA-related genes PALB2 and BRIP1, which are rarely present in OC. What is even more striking is 
that apparently there was complete segregation of the mutations in affected individuals, suggesting a 
penetrance level similar to BRCA1/2. Recently, a mutational screening of the RAD51C gene in a large 
series of 785 Spanish breast and/or ovarian cancer families identified 1.3% of mutations, and 
suggested the inclusion of the genetic testing of RAD51C into the clinical setting154. Investigators have 
recently sequenced RAD51D in 911 wild-type BRCA1/2 breast-ovarian cancer families as well as 
1,060 controls155. Inactivating mutations were identified in 8 out of 911 breast and ovarian cancer 
families (0.9%), 0 in 737 BC families, and 1 in 1060 controls (0.09%). There was a higher prevalence 
of mutations in families with more cases of OC. The RR of OC for carriers of deleterious RAD51D 
mutations was estimated at 6.3 (95% CI 2.86–13.85) whereas RR of BC was non-significantly 
increased. New data support the previous observation that loss-of-function mutations in RAD51D 
predispose to OC but do not to BC. The XRCC2 and XRCC3, members of RAD51 family, maintain 
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chromosomal stability during HR156. A homozygous frameshift mutation in XRCC2 being associated 
with a previously unrecognized form of FA was recently reported157. XRCC2 binds directly to the C-
terminal portion of the product of the BC susceptibility pathway gene RAD51, which is central to HR. 
XRCC2 also complexes in vivo with RAD51B (RAD51L1), the product of the breast and ovarian 
cancer susceptibility gene RAD51C9 and with the product of the OC risk gene RAD51D, and localizes 
together on sites of DNA damage158. An exome-sequencing study of families with multiple BC 
individuals identified two families with XRCC2 mutations. One of them with a protein-truncating 
mutation and the other one with a probably deleterious missense mutation159. From other XRCC genes 
investigated, XRCC1 399Gln allele acts as a recessive allele in association with BC risk160. 
 
Breast cancer low-risk alleles 
Part of the unexplained fraction of familial relative risk is likely to be explained by a polygenic model 
involving a combination of many individual variants with weak associations to risk, the so called low-
penetrance polymorphisms. The frequency of these alleles may range from 5% to 50% and could 
possibly be higher in families with BC. Individually they only have a small effect on BC risk (relative 
risk ≥1.01 and <1.5). Nevertheless, they may collectively account for a large component of BC 
heritability. 
Other identified loci associated with BC in large studies involving thousands of subjects are, MAP3K1 
(mitogen-activated kinase 1), LSP1 (lymphocytespecific protein), and TNRC9 (trinucleotide 
repeatcontaining 9), along with a 110 kb region of chromosome 8q24161. Associations with other 
chromosomal regions, 2q35, 5p12, 6q22, and 16q12, also have been reported162. Further analysis 
showed that allelic variation at FGFR2, TNRC9, 8q24, 2q35, and 5p12 are associated with 
physiological characteristics of breast tumours, such as ER status163. Moreover, it has been shown that 
specific FGFR2, MAP3K1, and TNRC9 variants may interact with BRCA1 and BRCA2 mutations to 
increase BC risk164. 
 32 
Circulating	cell-free	DNA	(cfDNA)	
 
The first description of the presence of DNA freely circulating into the bloodstream dates back to 
1948, when Mandel and Métais identified extracellular nucleic acids in blood of both healthy and 
diseased people165. 
History	
During the 60s several studies conduced in patients affected by Lupus Erythematosus (LE) discovered 
important features of DNA in blood. Ceppellini and colleagues identified a DNA-reacting factor in 
serum obtained from a patient affected by LE Diffusus. Starting from the hypothesis that DNA can 
elicit specific antibodies (Ab), they purified DNA from different samples of both human and animal 
origin and verified if they observed a reaction after incubation with serum. The choice of a LED 
affected patient was due to two main reasons: a) nuclear material released by nucleolysis, that is 
typical of this disease, can get in contact with immunological components; b) subjects affected by LE 
produce a huge amount of auto- and iso-Ab, thus increasing the probability to have anti-DNA Ab166. 
They effectively observed a factor able to interact with DNA from different sources and species that 
behave like an antibody, but the fact that other sera obtained from eight other patients did not showed 
reactivity drive the explanation of the phenomenon toward a patient-specific autoimmune 
hyperreactivity166. 
Following experiments demonstrated not only an association between the presence of anti-DNA Abs 
in the serum and the acute phase of SLE, but also the interaction between these Abs and autologous 
DNA in addition to eterologous ones, suggesting an active role of the DNA-anti-DNA complex in 
disease progression, in particular in driving renal disease and vasculitis167. 
Two years after, Tan and colleagues started from these discoveries to set up a technique to detect 
soluble tissue antigens, among which we find DNA, in SLE patient’s blood and that can react with 
Abs to produce renal injury. They demonstrated the possibility to use sera obtained from SLE patient 
to detect the presence of DNA in blood. Starting from calf thymus DNA, they performed experiments 
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on DNA-anti-DNA recognition in three different settings: native DNA (i.e. dsDNA), sonicated DNA 
(i.e. small dsDNA fragments) and heat denatured DNA (i.e. ssDNA). They did not observed 
differences in reaction between native and sonicated DNA, suggesting an identical antigenicity of the 
two DNAs. The difference was observed in ssDNA and, more interestingly, serum that had reacted 
with dsDNAs was able to react also with ssDNA, suggesting the presence of Abs recognising the two 
forms independently168. The complete abolishment of the reaction after DNase treatment of the sera 
pointed definitely toward DNA as the antigen in sera168. 
Even if the presence of DNA in plasma of patients affected by cancer was demonstrated by Tan and 
colleagues in 1966, it took around a decade to specifically study how circulating DNA behave in 
cancer-affected patients. Leon and colleagues developed a radioimmunoassay to quantify ng quantities 
of DNA, based on [I125] iododeoxyuridine-labeled DNA working as antigen and LE patient’s serum as 
source of Abs. They evaluated the amount of cfDNA in serum of 173 cancer patients and 55 healthy 
people with this assay, identifying a median concentration of DNA of 13 ± 3 ng/ml plasma and 180 ± 
38 ng/ml plasma in healthy and cancer patients, respectively. They also detected higher amount of 
DNA in patients with metastatic cancer respect to nonmetastatic ones169. 
The application of the assay after radiation therapy of the patients revealed a decrease amount of 
cfDNA in those patients in which clinical conditions improved, i.e. decrease of tumour size or 
reduction of pain, whereas a lack of response to the therapy was associated to increase or no changes 
in DNA levels169. 
One of the critics that can be moved to these results concerns the 50% of patients affected by cancer 
that showed DNA levels comparable to healthy people. This scenario can be explained by the fact that 
the only inclusion criteria of this research was to be selected for radiation therapy without taking into 
account previous surgery or chemotherapy that could have affected the amount of free DNA169. 
These data taken together suggested the hypothesis that also tumours are capable to release circulating 
DNA, as previously observed by this group in cultured human normal lymphocytes170 and confirmed 
by the analysis of DNA released in the medium by leukemic cells obtained from a patient, even if 
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conditions that drive this phenomenon were not known. Researchers finally hypothesized that 
cancerous DNA can play a transfectant role and contribute to the diffusion of the tumour171. 
All these information were reinforced in the first half of the 90s, when researchers started analysing 
cfDNA at molecular level. In particular Vasioukhin and colleagues looked at K-RAS mutation in 
circulating, tumour and blood-isolated cell DNA of patients affected by colorectal adenocarcinoma172 
and N-RAS mutation in DNA obtained from plasma, circulating cells and bone marrow of patients 
with myeloid leukemia or myelodisplastic syndrome173. Interestingly, N-RAS mutations identified in 
the plasma DNA were not always detected analysing the other sources of DNA. This observation had 
strong medical implication: absence of the mutation in blood cells can be linked to the apparent 
remission state of patients or to the fact that cancer cells can remain into bone marrow; no 
identification of mutations into bone marrow DNA can be explained by the fact that needle biopsy 
collect just a small fraction of bone marrow, thus it is likely that not all the malignant clones are 
included into the analysis. 
This last observation can be considered a precursor of the ‘liquid biopsy’ concept: the possibility to 
identify a mutation in plasma DNA, avoiding biopsy invasiveness and its associated risks and reducing 
the probability to miss the malignant clone, can furnish fundamental clinical information, considering 
that presence of RAS mutations in myeloid disorders is a poor prognostic factor at diagnosis174 and 
reflects efficacy of chemotherapy in achieving clinical remission175. 
Nearly in the same years, another clinical setting become involved in cfDNA study. In 1997 Lo and 
colleagues firstly described the presence of fetal DNA in both plasma and serum of pregnant women, 
by amplifying Y sequences in male fetus bearing women176. This discovery paved the way toward 
non-invasive prenatal diagnosis of fetal trisomies and genetic anomalies, such as Down syndrome177, 
but also important biological characteristics such as sex178 and Rhesus factor or blood group179. Even 
more interestingly, the possibility to analyse extracellular DNA released by embryonic cells in culture 
can prevent the aspiration of one or two cells from embryos after in vitro fertilization (IVF) with the 
conceivable complications and risks associated to the procedure, thus maintaining the levels of 
information obtained by sequence and structure analysis180,181. 
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Biological	features	of	cfDNA	
Fragment size 
We have already described the work done by Tan and colleagues in 1966, that demonstrated the 
presence of DNA-anti-DNA complexes in blood of SLE patients. The isolation of the DNA-anti-DNA 
complex allowed a better characterization of circulating DNA. It was demonstrated that DNA in these 
complexes is double stranded and fragments were of 30-40 bp in length182. 
The first evidence of tumour-released cfDNA and its characterization came up in 1987 with Stroun 
and Anker work. They analysed circulating DNA from patients with different malignancies. They 
firstly confirmed that DNA in cancer patient is mainly double stranded and observed a heterogeneous 
fragment composition, with size of the fragments ranging between 21 kb to less than 500 bp, thus 
smaller than genomic DNA183. 
The application of an in vitro DNA synthesis test, consisting in a DNA synthesis reaction performed in 
presence of carcinogens, allowed to determine if DNA was originated from cancer, if the reaction 
takes place, or normal cells, i.e. no synthesis. Results of this test confirmed the presence of cancer-
derived circulating DNA in 5 out of 7 samples analysed, while the other 2 presented only non-tumoral 
DNA. The hyperchromicity test performed on these samples revealed an increase in absorbance in all 
the samples in which DNA synthesis occurred, suggesting that amplified DNA was characterized by 
double strand instability, a typical characteristic of tumoral DNA184. 
Fragmentation profiles revealed the coexistence of at least three sets of fragments, characterized by 
different length: 
- 180-200 bp fragments and their multiples 
- more than 10000 bp fragments 
- fragments smaller than 150 bp 
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Signature of the release mechanism 
The description of cfDNA fragment composition can furnish several information on processes 
generating these fragments. 
The analysis of cfDNA by PAGE in cancer patients performed by Jahr and colleagues revealed two 
main sets of fragments well distinguishable on the base of their size. Despite a strong variation 
between samples, they observed two main sets of fragments well distinguishable on the base of their 
size. They observed a mono and oligonucleosomal DNA ladder, i.e. DNA of ~180 bp and multiple 
thereof in lengths, and a high molecular weight fraction of ~ 10000 bp. 
Model studies on both cell lines and animals confirmed apoptosis and necrosis as the two mechanisms 
generating the oligonucleosomal ladder and the high molecular weight fraction, respectively185. 
A third set of fragments, that is probably the most clinically relevant among cfDNA, was discovered 
nearly a decade after these findings. 
Mouliere and colleagues, in fact, observed a great variation in cfDNA quantification on the base of the 
length of the amplicon amplified by PCR. In particular, they determined that nearly 80% of tumoral 
derived cfDNA was missed when 150-300 bp amplicons are used for the analysis and suggested 
amplicons of <100 bp as the best (Fig. 2).  
The fact that most of the cfDNA fragments originated by tumour are smaller than 145 bp, i.e. are 
characterized by a reduced DNA integrity, can be explained with an increased apoptotic rate. This data 
strongly correlates with the high proliferation and apoptosis rates observed in tumours and supports 
apoptosis as an important source of tumoral circulating DNA186,187. 
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Fig.2 : cfDNA fragment size distribution of mutant and wild type cfDNA. A) plasma of CRC affected patients 
B) xenografted animal model. From Mouliere et al, 2011. 
 
The identification of tumour causative mutations172-173 or the lower length of fragments186,187 clearly 
indicates that tumours produce and release DNA fragments into the bloodstream. 
The identification of cfDNA in healthy people raised the question on which tissues contributes to this 
population. The lacking of a genetic biomarker, as mutations, that clearly indicates the origin of the 
fragment has been a limitation in this field and in those pathological conditions associated with an 
increased cfDNA, such as myocardial infarction188, stroke189 or autoimmune disorders190, that do not 
present a genetic discriminant between healthy and pathologic cellular status. In this scenario, Snyder 
and his colleagues pointed out nucleosomal occupancy as a powerful marker of contributing tissues. 
Starting from the established association between cfDNA fragments and nucleosomal DNA, they 
hypothesized that cfDNA sequences must reflect at least in part the epigenetic landscape of the cell, 
and thus tissue, of origin. By deep sequencing of cfDNA fragments and maps of nucleosomal 
occupancy, they were able to indicate lymphoid and myeloid cell lines as the source of physiological 
cfDNA, confirming previous works191, and revealing the contribution of different tissues in samples of 
different cancer patients192. 
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An alternative “genotype-independent” method to analyse cfDNA focused on methylation. It is widely 
established that cancer harbours specific DNA methylation patterns and epigenomic profiling can 
furnish important clinical issues in diagnosis, prognosis and disease monitoring and can be considered 
a marker of tumour DNA193.  
Cancer-associated methylation modifications, as nucleosomal occupancy described earlier, are more 
widely applicable approaches compared to tumour-specific mutations that require knowledge of the 
patient specific mutational profile or the application of libraries of assays covering common mutation. 
Lehmann-Werman and colleagues analysed patients affected by various diseases to identify, through 
cfDNA methylation analysis, cell death in different tissues. They firstly identified tissue-specific DNA 
methylation patterns and then looked at those markers into cfDNA. They were this way able to 
identify pancreatic β cells as the source of cfDNA in insulin-dependent diabetic samples, 
oligodendrocytes in patients affected by multiple sclerosis, neuronal/glial origin of cfDNA after both 
cerebrovascular accident or heat attack and exocrine pancreatic cell in subjects with pancreatitis or 
pancreatic cancer194. 
cfDNA bioavailability 
A critical step in cfDNA comprehension concern mechanisms by which it is released and circulates 
into the bloodstream and how it interacts with other cells (Fig. 3). 
 
Fig. 3: potential vesicles that transport cfDNA. From Thierry et al. (2016). 
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Apoptotic	bodies	
Apoptotic bodies have been addressed as a source of cfDNA, even if nowadays there are still open 
questions on this hypothesis. These vesicles measure 1-5 μm, are produced in the late stage of 
apoptosis by membrane blebbing and contain part of the cytoplasm and DNA degraded by caspase-
activated DNase during apoptosis195, 196. 
Surely the characteristic ladder pattern observed in cfDNA185 indicates apoptosis as a source of cfDNA 
and, as a result, apoptotic bodies as the way in which it is released. Several studies associated the 
amount of cfDNA to apoptosis of neoplastic cells due to fragment composition and comparison with 
other markers of apoptosis. 
On the other hand, apoptotic bodies should be cleared in situ by epithelial cells and macrophages, thus 
contribution to circulating DNA should be limited195. 
 
Microvesicles	
Microvesicles are membrane-surrounded particles containing an aqueous compartment. 
It has been observed that cancer patients produce an abnormal amount of microvesicles that are 
released into the bloodstream186, 197. These structures are strictly associated with cfDNA and are a way 
of genetic information transfer and cell-to-cell communication198, 199. 
Depending on the process generating them, microvesicles are divided into exosomes: 30-100 nm in 
diameter, these structures are secreted by most cells and can transfer material laterally, i.e. horizontally 
between different cells. They contain proteins, particular lipids, messenger RNA (mRNA), micro RNA 
(miRNA) and variable amount of DNA200. Interestingly, it has been demonstrated that this DNA 
component is characterized by two sets of fragments: a membrane-bound, large size dsDNA and a 
small fragment DNA inside the exosome200. More recently, Rohan-Fernando and colleagues observed 
that a large proportion of plasma cfDNA is localized into exosomes201. 
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Macromolecular	complexes	and	the	Virtosome	
The possibility that DNA circulates in macromolecular complexes was confirmed in several SLE 
studies, describing the association between DNA and Abs. A new macromolecular complex was 
discovered in 2010 by the Stroun group, who firstly described a DNA/RNA-lipoprotein complex that 
is released in a regulated fashion202. This discovery confirmed studies on active release of DNA in the 
medium of cultured lymphocytes203,170, frog heart auricles204, rat spleen205 or leukemia cell line HL-
60206 and the hypothesis of an active DNA release mechanism195. 
Further studies on this complex revealed that all the components are newly synthesized only by living 
cells170,195,205, the complex is released in a energy-dependent process205 and in a controlled 
manner170,195. Analysis in chick embryo fibroblasts demonstrated that this complex could be uptaken 
by cells207. 
	
Extracellular	DNA	Traps	
It is well known that both neutrophils and eosinophil are involved in tumour-associated inflammatory 
infiltrate, and both are able to generate extracellular DNA traps, i.e. DNA associated with other 
cellular structures. 
Neutrophils in tumour microenvironment can acts as both pro- and anti-tumorigenic, depending on 
their activation status. In particular, NETosis is a cell death program following neutrophil activation 
consisting in chromatin decondensation, lysis of membranes and neutrophil extracellular DNA traps 
(NETs) release208. This complex of DNA fibers and anti-microbial granules is involved in pathogen 
trapping and killing209. There is also a so-called “vital NETosis”, a process in which NETs are released 
without cell lysis210. 
Eosinophil extracellular DNA traps (EETs) are released under eosinophil activation and are composed 
of only mitochondrial DNA, actively secreted by a catapult-like manner211. An important feature of 
EETs is that eosinophils remain viable during this process and no “EETosis” is evidenced211,212. 
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So far NET release has been described in several pathological conditions, such as infections, 
autoimmune pathologies, trombotic illnesses and inflammatory response213,214, metastases promotion 
and progression215,216 or after exercise217, that are characterized by high cfDNA levels, suggesting a 
contribution of this structure to circulating DNA population. 
 
Serum	Proteins	
Since the 60s it is well known that both single and double strand DNA can interact with Ab, forming 
the so-called DNA-anti-DNA complex, that is involved in SLE progression167,168. 
It has been described that DNA can link with proteins, considering its electrostatic nature, in particular 
with albumin, fibronectin and the C1q complement component218. 
Thus, pathological conditions altering serum protein availability can affect the amount of cfDNA in 
blood181. 
 
Cell	Surface-Bound	cfDNA	
Both DNA and RNA can be found on leukocytes and erythrocytes membranes218. In vitro studies 
revealed 20 kbp DNA fragments on cell surfaces219, either naked or associated with macromolecules. 
cfDNA half life and clearance 
Starting from the 60s, several works were focused on deciphering free circulating DNA half life and 
kinetics. Tsumita and Iwanaga firstly studied externally introduced DNA fate by detecting 
radioactivity at different times after tritiated calf thymus DNA injection into mice. They observed two 
phases of radioactivity decrease: the first was quite rapid, 30 mins, and corresponded to >99% 
reduction in radioactivity; the second presented a slow decrease in radioactivity loss. Analysis of 
organs revealed that kidneys represented the main way of excretion, even if a fraction of radioactivity 
was trapped in liver tissues even 3h after injection220. Chused et al implemented previous data by 
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analysing clearance of dsDNA and ssDNA in different mice strains. They observed that ≥50% of 
injected nucleic acids, whether ss or ds, was cleared in 1 min, rising to 90% in 20 mins, with 
denaturated DNA removed slighty faster than dsDNA. Incubation with endogenous nucleases revealed 
that most of the DNA is uptaken as macromolecule or complexed with antibodies, more than digested, 
and analysis of organs suggested a pivotal role of liver and spleen, via reticulo-endothelial uptake, in 
DNA clearance221. 
Dorsch and colleagues compared clearance rate of ssDNA in rabbits non-immunized and immunized 
with ssDNA, obtained by heat denaturation. 
They injected both rabbits with I125-calf thymus ssDNA and they observed an inversely correlated 
relation between clearance rate and relative amount of anti-DNA antibodies in immunized rabbit, i.e. 
the presence of anti-ssDNA Abs delayed ssDNA clearance and persistence of DNA-anti-DNA 
complexes can affect pathogenesis of immune complexes disease. 
These observations seemed in contrast with the high levels of circulating DNA observed in SLE 
patients. Emlen and Mannik thus hypothesized that in some conditions either DNA clearance is 
altered, or SLE DNA is somehow different from experimental DNA or larger amounts of DNA are 
released. 
To better understand this phenomenon, they administered several doses of I125-ssDNA, ranging from 2 
μg to 500 μg, and collected blood at different times (30 s - 8h). As expected, ssDNA at doses 
comparable to previous experiments was cleared in an analogous time and the liver was the main 
organ involved, suggesting phagocytosis by Kupffer cells as the main physiological process at the base 
of clearance. As phagocytosis is a process subjected to saturation, an amount of ssDNA higher than 
the threshold can explain why DNA can accumulate into the bloodstream. The kinetics observed for 
high dose ssDNAs effectively were saturable for both blood clearance and liver uptake processes. 
Kidneys showed an uptake independent on DNA dose administered, in the amount of 2-5% of total 
removal, and spleen started uptaking DNA once liver got saturated but played a minor role in the 
process. Data obtained supported a circulating endonuclease that rapidly cleaves large molecular 
weight ssDNA into smaller fragments that, as well as big ssDNA fragments, are bound to the liver 
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where a membrane exonuclease release nucleotides into bloodstream. The latter step is the one that 
gave the saturable feature at the system, supporting the fact that SLE patients show high levels of 
circulating DNA222. 
Pancer and colleagues observed that splenic lymphoid cells maintained in culture spontaneously 
released into the media a unique species of DNA of 145-185 bp in length, predominantly double 
stranded and able to induce anti-DNA Ab, against both ssDNA and dsDNA, if injected into mice223. 
In 1984 Emlen and Mannik went deeper in understanding DNA behaviour studying clearance and 
organ uptake of both ssDNA and dsDNA of different sizes in normal mice. Clearance presented two 
exponential components: organ uptake, that was more rapid for ssDNA than dsDNA, and excretion of 
waste products, that did not showed differences between different preparations. They concluded that 
ssDNA is cleared in around 20 mins mainly by the liver, while dsDNA remains in the circulation 
longer, till 40 mins, and is mainly metabolized by circulating nucleases. This latter result can also 
explain why SLE patients, who are characterized by lower levels of nucleases into the bloodstream, 
can accumulate circulating dsDNA that forms DNA-anti-DNA complexes224. 
A direct analysis of cfDNA was performed by Lo and colleagues in 1999. They looked at fetal 
circulating DNA clearance in 8 pregnant women about to give birth and observed a two phases process 
that pointed out a median 16.3 mins half-life for cfDNA225. Several years after, a massively parallel 
sequencing approach indicated a 1h half life for the first phase and a 13 h half life time for the second 
phase226. 
The analysis of post-surgery cfDNA clearance in a patient affected by CRC revealed a half life of 114 
mins227. 
Discrepancies observed in half-life determination can be explained accounting for different clinical 
and experimental settings, i.e. externally injected DNA vs effective cfDNA, model organisms vs 
patients, different pathological conditions, and a still not clear characterization of release rate, but 
determination of fate and turnover of cfDNA is necessary to comprehensively understand the 
biological role of cfDNA and to develop tools for biomedical and clinical applications181. 
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cfDNA	functions	
Several functions have been attributed to cfDNA, on the base of its structure and way of circulation. 
Intracellular messenger 
We have already described Stroun, Anker and Gahan works that described virtosome202. Studies on 
intracellular messengers date back to the 60s and involved the concept of non-sexual transmission of 
characters observed mainly in plant species and graft experiments. Experiments on plant grafts 
revealed that characteristics of the graft are transmitted to the progeny, originated by the stock228. An 
analogous situation was observed in feather colour modification in white chickens after blood 
transfusion from Guinea hens228. 
The discovery of virtosome and its active and regulated secretion in the medium of cultured cells 
suggested virtosome could play an intracellular messenger role. 
Actually, the virtosome ability to penetrate into cells was demonstrated much earlier than its 
description. Several works described the intercommunication between different types of cells already 
in the 80s. it was already known that lymphocytes in culture release actively and spontaneously newly 
synthesized DNA into the culture medium170. Experiments on T and B cells in culture revealed that T 
cell released DNA after HSV exposure was able, once added to B cell culture medium, to induce anti-
HSV antibody synthesis by unexposed B cells. More interestingly, those Ab presented peculiar anti-
allotypes of T cells229. Analogous experiments were performed on mice that were injected with DNA 
released by T cell in the medium after HSV or polio virus exposure. Parallel to the previous 
experiment, mice started producing human-like anti-polio and anti-HSV Abs230.  
 
Genometastases 
Strictly associated to the ability to act as an intracellular messenger is the concept of genometastases, 
i.e. the capacity of tumoral cfDNA to transfect healthy cells far from the primary tumour and this way 
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direct the formation of metastases. The possible involvement of cfDNA in oncogenesis was 
hypothesized back in 1965, when it was observed that the injection of tumour DNA in mouse 
bloodstream results in tumour development231. In 1994, Anker and colleagues observed that NIH/3T3 
cells grown into medium of cultured SW480 cell, that carry a K-RAS mutation, acquired the mutation 
identified in SW480 and became tumorous173. An analogous situation was observed with the addition 
of plasma obtained from colorectal cancer patient carrying a mutated KRAS232. Furthermore, NIH/3T3 
cells treated this way were able to induce tumour formation once injected in nude mice232 (Fig. 4). 
 
Fig. 4: schematic representation of genometastases proving experiment. Plasma from colon 
cancer patients, containing DNA carryng the mutated K-RAS (GAT trinucleotide), added to 
the medium of NIH/3T3 (wild type K-ras) resulted in the acquisition of the mutant K-RAS 
from the cells. Mice injected with the transformed cells develop K-RAS mutated tumors 
(from Garcia Olmo et al, 2010). 
 
Mechanisms sustaining this phenomenon can be multiple and involve several cfDNA carriers. All the 
cfDNA-containing vesicles, i.e. apoptotic bodies, microvesicles and exosomes, can be responsible for 
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genetic material transfer233. Nucleosomes are equally able to cross plasma membrane, thus penetrating 
into the cell234. Macromolecular complexes involving proteins into the bloodstream also favours DNA 
internalization. The virtosome, finally, has a clear ability to penetrate into cells and alter their genetic 
landscape, as shown by experiments on NIH/3T3 cells described earlier. 
A series of experiments shed light on events that follow cfDNA uptake. Mittra and colleagues 
discovered that cfDNA, once uptaken, is integrated by host cells into their genome235 and that this 
event induces apoptosis and DNA damage responses235 (Fig. 5). 
 
Fig. 5: induction of g-H2AX, an indicator of dsDNA breaks, and active Caspase-3, an 
indicator of apoptosis, in NIH/3T3 cells treated with fragmented circulating DNA (DNAfs). 
DNAfs from cancer patients (grey bars) induces a higher response compared to those 
coming from healthy donors (adapted from Mittra et al, 2015). 
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Pro-inflammation mediator 
 
It is well known that DNA is an immunostimulating molecule, considering its double-helix structure, 
the ability to interact with other molecules and sequence motifs. This data is supported by the 
observation of activation of interferon (INF) and pro-inflammatory molecules secretion in cells of the 
innate immune system after DNA exposure236. The abundance of nucleic acid specific receptors 
further supports an immunological function of DNA237. We have already described the role of 
circulating DNases in maintaining scarce levels of DNA, thus blocking its ability to stimulate cells, 
and the case of SLE patients, presenting low levels of DNase activity, characterized by autoimmunity 
and accumulation of cfDNA. 
Several studies indicate that cfDNA acts like a damage-associated motif pattern (DAMP), i.e. 
endogenous ligands that can be recognized by Toll Like Receptors (TLRs) and activate the TLR-
MyD88 (Myeloid differentiation primary response gene 88) pathway, leading to NF- kB and AP1 
production238 (Fig. 6). These transcription factors, then, regulate the expression of inflammatory 
cytokines, as tumour necrosis factor or interleukines (IL) 1 and 6, and costimulatory molecules such as 
CD80 and CD86239. 
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Fig. 6: schematic representation of the interaction between DNA and TLR9 receptor. 
DNA internalization is facilitated by class III Phosphatidylinositol 3-kinase. Once in 
the endosome DNA binds to TLR9 and TLR-MyD88 pathway is activated. Several 
downstream factors are activated, leading to NF-kB and AP1 activation and gene 
transcription. CpG ODN: CpG OligoDeoxyNucleotides (from Klinman, 2004). 
 
TLR9 is a DNA receptor that recognizes oligonucleotides of 20-30 nt containing demethylated CpG 
motifs. For this reason, it is physiologically involved in sensing microbial DNA, either viral or 
bacterial, and it is usually located into intracellular vesicle membranes in dendritic cells and 
macrophages. The expression of TLR9 has been evidenced also in cancer cells and its high levels are 
associated with poor survival in patients affected by several cancers, among which glioma, prostate 
and esophageal adenocarcinoma. Even if a direct correlation between cfDNA and TLR9 in cancer has 
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not been determined, the hypomethylated DNA profile in several cancers can be a condition favouring 
cfDNA and TLR9 interaction and subsequent effects on cancer cells240. 
A study on CRC derived cell lines revealed that cfDNA of tumour origin is able to induce 
proliferation, promote cell migration and invasion and stimulate secretion of IL8, which has a pivotal 
role in malignancy, due to interaction with TLR9240. 
 
Tumour progression 
Discovery of NETS and EETS opened a new field of investigation. NETS, in particular, have already 
been associated to cancer progression241. 
Polynuclear cells produce NETS and EETS after stimulation by pathogens and/or particular 
pathophysiological conditions, as inflammation242. Polynuclear neutrophil levels in the bloodstream 
correlate negatively with overall survival rate, due to their involvement in forming “bridges” between 
circulating tumour cells and epithelia of both lung and liver. It has also been demonstrated that NETS 
can sequester circulating tumour cells promoting metastasis formation by increasing adhesion to 
epithelial cells243. 
 
Therapeutic target 
Considering all these physiological and pathological conditions in which cfDNA is involved, it can be 
reasonably considered a potential target for therapies. In particular, tumour progression via 
genometastases and DAMP-induced activation of the immune system are the main field in which 
therapy can be hypothesized. 
Experiments on cancer cell lines xenografted onto mice were used to verify the efficacy of DNase and 
RNase treatments. Lung tumour-bearing mice treated daily with low doses of DNase and RNase 
presented reduced metastatic progression244 (Fig. 7). Reduced tumour progression was observed also in 
mice injected with DNA obtained from the medium of SW480 cell cultures, after DNase treatment245. 
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Fig. 7: Effects of RNase A and DNase I treatment on metastasis development in a Lewis 
lung carcinoma (LLC) metastatic mouse model. As we can see, lung lobes in control 
animals are characterized by several large metastasis (arrow). Mice treated with either 
RNase A (second line) or DNase I (third line) showed a great reduction in metastasis 
number and dimension (from Patutina et al, 2011). 
 
NETS destruction can be achieved with either DNase or neuro-elastase inhibitors243. 
A third therapeutic option involves cationic polymers that electrostatically interact with cfDNA 
inhibiting the inflammatory response without affecting immune system246. 
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MATERIALS	AND	METHODS	
Project	structure	and	inclusion	criteria	
This research project was submitted to the Ethics Commitee of the Circolo Varese Hospital and, after 
receiving the approval, we started enrolling patients with Breast Cancer who underwent surgery at the 
Senology Research Center - ASST Sette Laghi Varese. 
This is a monocentric, explorative and translational study. 
Inclusion criteria are: a) only female patients; b) cytologically or histologically confirmed breast 
cancer; c) candidate for surgery; d) no exclusion on the base of histological subtype or lymph node 
involvement; e) diameter size of the neoplasia: ≥ 20 mm; f) no previous detection of gene mutation 
(i.e. sporadic cancers, no BRCA1-2 mutated patients). 
Exclusion criteria consist of : a) previous breast cancer (i.e. recurrence); b) the patient has undergone 
treatments, either chemotherapy or radiotherapy. 
 
Validation	of	the	extraction	protocol	
Samples	collection	
We firstly collect samples to validate the extraction protocol. Considering that patients presenting 
neoplasia bigger than 2 cm in diameter are not so common, we decided to perform this step including 
also samples with smaller tumours. 
Blood was collected from 13 patients with an average age of 62 yo (range 43-88 yo), neoplasia 
diameter of 15 mm on average (range 2-28 mm) and no BRCA 1-2 mutations. Data are summarized in 
Table 4 (see results). 
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Blood	collection	and	plasma	isolation	
We collected 10 ml of peripheral blood in K3EDTA tubes commonly used for molecular applications. 
Plasma was isolated within 30 mins from the collection of blood in order to minimize the risk of white 
blood cells (WBCs) haemolysis. 
Plasma isolation was performed as follow: 
- Blood is firstly centrifuged at 1600 xg for 10 minutes to separate blood cells. 
- Supernatant is collected and transferred to 1.5 ml microcentrifuge tubes, being careful 
not to take away cells or proteins. 
- Supernatant is centrifuged again at 12000-16000 xg for 10 mins, in order to remove 
cellular debris. 
- Plasma is collected and transferred to new microcentrifuge tubes, being careful not to 
collect pellet formed at the bottom of the tube. 
- The obtained plasma is processed immediately or stored at -80° C. 
We decided to exclude from the analysis all those samples that present any sign of haemolysis (i.e. 
those plasma whose colour show any shade of red). 
cfDNA	extraction	
We decided to firstly compare two different extraction procedures, both automatized, one working on 
the MaxWell® RSC (Promega) platform with the MaxWell® RSC ccfDNA Plasma Kit (Promega), 
and the other working on the Abbott m2000sp (Abbott). 
The extraction with MaxWell® RSC was done on 1 mL of plasma obtained as previously described. 
The quantification step was performed using both the fluorometer associated to the MaxWell@ RSC 
instrument and the Qubit™ dsDNA HS Kit (Thermo Fisher). The second extraction was performed on 
a volume of 300 μL of plasma and the quantification was performed with the Qubit™ dsDNA HS Kit 
(Thermo Fisher). 
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Due to the limited amount of cfDNA obtained and to avoid the risk to consume all the material for just 
one analysis, we decided to evaluate extraction protocols that allow us to scale up the starting volume 
of plasma. 
We had the opportunity to test the NextPrep-Mag cfDNA isolation kit (Bioo Scientific) and the 
QIAamp MinElute ccfDNA Midi Kit (Qiagen), whose protocols allow to scale up the extraction till 3 
mL and from 3 to 10 mL of plasma, respectively. 
Both kits are based on magnetic beads purification of cfDNA. The Qiagen one uses beads to collect 
and concentrate cfDNA from plasma and then the purification is based on columns, while the Bioo 
Scientific kits requires the use of magnetic beads in all the steps of the protocol. We performed both 
protocols following manufacturer instructions. 
We validate the extraction protocols with samples from a different project and we decided to proceed 
with the QIAamp MinElute ccfDNA Midi Kit extracting from a starting volume of plasma of 4 ml. 
 
Preservative-containing	tubes	
We then test the utilization of the Blood STASIS 21-ccfDNA tubes (MagBio Genomics Inc.). These 
tubes are specific for cfDNA isolation due to the presence of an additive that stabilize cells and 
prevent coagulation, thus reducing the risk of genomic contamination by blood cell haemolysis and 
stabilizing cfDNA levels when stored for up to 21 days at room temperature. 
16 mL of blood were collected into 2 Blood STASIS tubes and centrifuged as described above. 
We then extract in parallel cfDNA from plasma obtained from Blood STASIS 21-ccfDNA and 
common K3EDTA tubes with the QIAamp MinElute ccfDNA Midi Kit. 
Amount of cfDNA obtained from Blood STASIS 21-ccfDNA tubes was higher than K3EDTA ones, 
being equal the haemolysis of the plasma. 
We thus decided to proceed collecting samples in Blood STASIS 21-ccfDNA tubes. 
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Experimental	project	
Sample	collection	and	plasma	separation	
We collected blood samples in Blood STASIS 21-cffDNA tubes and fresh tissue in culture medium 
from 19 patients that match including criteria indicated. 
Plasma has been separated as described in “blood collection and plasma isolation” paragraph. 
Fresh tissue has been placed in a culture media after surgery and then stored dry at -80°Cwithin 3 h. 
Genomic	DNA	extraction	
Genomic DNA has been extracted with the DNeasy Blood & Tissue Kit, starting from 25 mg of fresh 
tissue, following manufacturer instructions. 
The protocol consists of a first mechanical homogenization of the tissue followed by a Proteinase K 
digestion step and silica-based membrane purification with several centrifugations. 
DNA has been quantified with the Qubit dsDNA BR kit (Thermo Fisher) following manufacturer 
protocol. 
cfDNA	extraction	
Circulating DNA has been extracted as described in the paragraph above “cfDNA extraction”. 
Target	sequencing	procedure	
Genomic DNA 
The preparation of genomic DNA, extracted from fresh tissue, was performed with the Homologous 
Recombination Solution by Sophia Genetics Kit (Sophia Genetics) and the Kapa™ Hyperplus Library 
preparation kit (Roche). These kits are usually used for formalin-fixed paraffin-embedded (FFPE) 
extracted DNA, characterized by DNA fragmentation and reduced molecule integrity. The usage of 
genomic DNA extracted from fresh tissue allows us to avoid these problems and have high-quality 
starting material. 
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As suggested by the protocol, we used the maximum amount of DNA, i.e. 200 ng, to generate high-
quality sequencing data. 
200 ng of DNA in a 25 µl volume are firstly enzymatically fragmented at 37°C for 20 mins, then the 
End Repair and A-tailing (ER&AT) two step procedure is performed, with an incubation at 20°C for 
30 mins anda second at 65°C for 30 minutes. Fragments are then ligated to Dual Index Adapters and 
the reaction is cleaned up using AMPure XP magnetic beads to remove all the reagents of the previous 
reactions. 
Libraries this way prepared are then amplified with a PCR reaction whose conditions are summarized 
in the Table 2 (below). Step 1st to 3rd are repeated 8 times. 
 
 Temperature (°C) Time (s) 
Lid 99  
Initial step 98 45 
1st step 98 15 
2nd step 60 30 
3rd step 72 30 
Final step 72 60 
Holding 10  
 
 
Amplified libraries are purified again with AMPure XP magnetic beads and individual libraries are 
quantified and their quality is evaluated. 
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2 µl of the purified library is diluted with 6 µl of nuclease-free water, quantification is performed on 2 
µl of the diluted solution with a fluorometric method while quality control (QC) is performed by 
capillary electrophoresis and library profile should present fragments ranging between 200 bp and 800 
bp. 
Libraries passing QC analysis are pooled mixing 300 ng of each library in a DNA low-binding tube; 
Blocking oligos and human Cot DNA are added to the mixture to mask adaptors and block nonspecific 
hybridization, respectively, and the mixture is lyophilized and stored at -20°C if not immediately 
utilized. 
Lyophilized libraries are resuspended in the Hybridation mix and hybridization step is performed as 
indicated by manufacturer (65°C for 4 to 16 hours). Streptavidin beads are used to bind and enrich 
hybridized targets by incubation at 65°C for 45 minutes. 
After a wash step to remove unbound DNA, the post-capture libraries are amplified. PCR conditions 
are listed in the Table 3 (below). 
 
 Temperature (°C) Time (s) 
Lid 99  
Initial step 98 45 
1st step 98 15 
2nd step 60 30 
3rd step 72 30 
Final step 72 60 
Holding 10  
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Steps 1st to 3rd are repeated for 15 cycles. 
Post-capture amplified libraries are cleaned up with AMPure XP magnetic beads and purified libraries 
are checked for concentration and quality, as described in the previous step of control. 
The last step of the protocol consists in library preparation for sequencing. Molarity of each pool is 
determined by the ratio between library concentration (ng/µl) and the product of the average size (bp) 
and 649.5 (Fig. 8) multiplied for 10^6. 
 
 
Pools are sequenced on MiSeq platform. 
 
cfDNA 
The preparation of circulating DNA was performed following the Solid Tumour Solution by Sophia 
Genetics protocol for circulating cell-free DNA (Sophia Genetics) and the Kapa™ Hyperplus Library 
preparation kit (Roche). 
Compared to the protocol described for the genomic DNA, this one does not include the enzymatic 
fragmentation, due to the fragmented nature of cfDNA. 
We decided to use as much cfDNA as we have, in order to reduce the risk of having bad results in 
library preparation and sequencing. Considering the low amount of cfDNA, the first PCR was set to 12 
cycles. 
The protocol starts from the End Repair & A-tailing step (ER&AT) and follows the one previously 
described for genomic DNA. 
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Data	analysis	
Data analysis was performed on the Sophia DDM® platform. A three-step procedure allows to rapidly 
and efficiently obtain information from row sequencing data. 
Step 1 consists in row data uploading and processing, resulting in a list of information. 
In step 2 results of step 1 are interpreted, thanks to the classification from highly pathogenic to benign 
made from the Sophia AI. 
Last step consists in a variant report definition. 
Variants detected were evaluated with the ClinVar (NCBI) database, that allows a direct association 
between the variant and its role in health. 
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RESULTS	
 
Validation	of	the	extraction	protocols	
Samples collected to validate the extraction procedure have been analysed as described in Matherial 
and Methods. Quantifications of the samples are summarized in Table 4 rappresented below (reference 
from materials and methods). 
 MaxWell™ RSC (Promega) Abbott m2000 (Abbot) 
SAMPLE ng/μL ng tot ng/μL ng tot 
E.coli 0.5 MF 0.096 5.664 <0.010 - 
87173141 0.100 5.90 <0.010 - 
87180260 0.067 3.95 <0.010 - 
87182036 0.110 6.49 <0.010 - 
87187622 0.060 3.54 <0.010 - 
87189259 (1) 0.138 5.38 <0.010 - 
87189259 (2) 0.248 9.67 <0.010 - 
87191680 0.185 10.92 <0.010 - 
117002299 0.0156 0.9204 <0.010 - 
117002296 0.0132 0.7788 <0.010 - 
117002837 0.0139 0.8201 <0.010 - 
117003112 0.0160 0.944 <0.010 - 
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Table 4: summary of quantification of cfDNA from samples coming from breast cancer affected 
patients used to validate the extraction procedure. 
 
The Table 5 (below) sum up characteristics of patients used to validate the extraction method. Thirteen 
patients were included, median age 62 years (range 43 – 88), the average diameter of the neoplasia 
were 15 mm (range 2 – 28). 
Ten patients underwent breast conservative surgery and only 3 had mastectomy. All had sentinel 
lymph node biopsy and in only two cases axillary lymph node dissection were performed. The average 
lymph nodes removed were 10 (range 4 – 18) and the average of metastatic lymph nodes were 1,7 
(range 1 – 3). 
The majority of the tumors (11 patients) were invasive ductal carcinoma with a moderate grade of 
differentiation (G2), only two patients were G3. Twelve had a strong positivity for the ER and PGR 
receptor status, 10 patients were HER2 negative and the average Ki67 were 15 (range 4 – 30). 
Ten patient underwent to complete adjuvant radiotherapy after breast conservative surgery. Almost all 
patients received adjuvant hormonal treatment, only 3 received also adjuvant chemotherapy. 
 
 
 
 
117003115 0.0128 0.7552 <0.010 - 
117003410 0.0127 0.7493 <0.010 - 
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Table 5 
 
 
Experimental	project	
DNA	extractions	
DNA obtained from patients enrolled in the project was extracted and quantified as previously 
described, starting from 4 mL of plasma. 
Genomic DNA was extracted from 25 mg of fresh tissue and quantified as described in Materials and 
Methods. 
Quantification of these samples are summarized in Table 6. 
  
 
13
62	y.o.	(range	43	-	88)
15	mm	(range	2	-	28)
all	negative
Mastectomy 3 negative 10
Lumpectomy 10 positive 3	(1	micro	MTS)
BLNS 13 n°	LN	MTS	average average	1,7	(range	1	-	3)
Lymph	node	dissection 0 n°	LN	removed average	10	(range	4	-	18)
BLNS	è	Lymph	node	dissection 2
ductal 11 G	1 3
lobular 2 G	2 8
G	3 2
positive 12 positive 3
negative 1 negative 10
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3
 62 
 cfDNA Fresh tissue 
SAMPLE ng/μL ng tot ng/μL ng tot 
Patient 1  0,35 8,75 49,4 7410 
Patient 2  0,39 9,75 35,1 5265 
Patient 3 0,56 14 42 6300 
Patient 4 0,26 6,50 40 6000 
Patient 5 0,65 17 71,1 10755 
Patient 6 1,07 20 85,9 12885 
Patient 7 0,26 1,3 47,1 7065 
Patient 8 0,44 2,2 47 7050 
Patient 9 0,14 3,5 46 6900 
Patient 10 1,42 35,5 163,3 24495 
Patient 11 1,16 29 144,6 21690 
Patient 12 0,07 1,75 42,1 2105 
Patient 13 0,93 23,25 33,8 5070 
Patient 14 3,17 79,25 229 34350 
Patient 15 8,7 174 150,5 22575 
Patient 16 17,4 348 207,2 31050 
Patient 17 28,3 566 63,8 9570 
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Target	enrichment	analysis	
Three runs of target enrichment and sequencing were by now performed. 
The first one comprised four samples of genomic DNA of patients 1 (ID 278399), 2 (ID 278400), 3 
(ID 278401) and 4 (ID 278402); the second one cfDNA samples of patients 1 (ID 293372), 2 (ID 
293373), 3 (ID 293374), and 4 (ID 293375); and the third genomic and circulating DNA of patients 5 
(IDs 295272 and 295274, respectively) and 6 (IDs 295273 and 295275, respectively). 
Figure 9 summarizes data regarding the total number of reads, those mapping and those with 
problemating matching of the three runs. 
 
 
Fig. 9: total, mapped and problematic read of the samples of the three runs.  
 
Quality of the sequencing was determined as mean phred quality score, distribution of raw reads 
quality and raw reads length. An example of data obtained is described in Figure 10. 
I run 
II run 
III run 
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Fig. 10: example of reads quality evaluation in genomic DNA of patient 1. A) Along Cycle 
Quality measure the phred score, i.e. an evaluation of the correct base call, along the dimension of 
the fragment. A phred score value of 30 corresponds to a 99,9% accuracy of the base called during 
the sequencing. B) Distribution of the raw reads length: the peak at the end of the scale indicates 
thatmost reads have a high length, i.e. are of good quality. C) Mapping quality distribution: the 
location of the peak indicates the quality of the mapping. Optimally, most of the mapping are of 
high quality with a peak around 40, generally the higher the peak the higher the quality is. 
 
 
Soft-clipping is a value associated to incomplete matching between the full length read and the 
reference genome. This data is essential to understand if a read can be considered in the analysis or 
must be discarded. In this protocol, percentage of no soft clip above 75% can be considered reliable.  
 
 
 
 
A B C 
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Fig. 11: pie chart illustrating the proportion of no soft clipping and soft clipping reads 
in genomic DNA of patient 1. As we can see in the box below the pie chart, >96% of 
the reads are no soft clipping, thus can be considered reliable. 
 
Mapping statistics give information on where the sequences mapped on the reference genome. This 
data indicated the accuracy of the target enrichment capture. If the sum of “onTarget” and 
“flankTarget” overcome 80%, target enrichment has captured the correct fragments, otherwise 
fragments in not-of-interest regions have been captured and analysed during the process (Fig. 11). 
The duplicate fraction percentage indicates if reads analysed are the result of an unbalanced PCR 
amplification or they belong to different amplicons. In genomic DNA analysis, this value should be 
between 20% and 40% to consider the analysis reliable, while values <20% can be considered 
excellent (Fig. 12). 
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Fig. 12: Mapping statistics of genomic and circulating DNA from samples 5 (IDs 295272 
and 295274, respectively) and 6 (IDs 295273 and 295275, respectively). As we can see, 
the sum of “onTarget” and “flankTarget” percentages is more than the 80% considered as 
a threshold for good capture results. 
 
 
Fig. 13: Analysis of the duplicate fraction of genomic (IDs 295272 and 295273) and 
circulating DNA (ID 295274 and 295275) from patients 5 and 6, respectively. Percentages 
observed in genomic DNA are below 20%, suggesting a low levels of PCR amplification 
unbalance. cfDNA samples, instead, have an higher percentage of sequences amplified by 
PCR. Columns named 2, 3, 4, 5, 6-10, 11-100 and >100 indicates total number of reads 
having an equivalent number of copies (2 means two copies, 3 three copies etc). 
 
Identification	of	mutation	
The Sophia DDM software analysis allows to identify among the sequences the presence of mutation/s 
and simultaneously to classify it on the base of their effect: 1 - benign, 2 - likely benign, 3 - uncertain, 
4 - pathogenetic and 5 - definitely pathogenetic. Those mutation that have not been described yet in 
the ClinVar database are classified on the base of their predicted role in: A - definitively pathogenetic, 
B - potentially pathogenetic, C - unknown significance. 
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The analysis also allows to distinguish between sequences presenting a low coverage respect to the 
threshold (x1000), i.e. are located in the “onTarget” region but data cannot be considered 
reliable,those retained, i.e. have an above threshold coverage and thus data can be analysed, and those 
called “low confidence” SNVs/INDELS, grouping modifications associated to intronic or untranslated 
(UTRs) regions predicted to be of unknown significance (class C). 
 
Patient 1 
The analysis of the genomic DNA highlighted only a pathogenic mutation in the RAD51B gene with a 
variant fraction (VF) of 5.2% and classified as definitely pathogenic. 
The mutation consists of an insertion of a 100 bp fragment between nucleotides 80 and 81that causes 
the formation of a stop codon, resulting in the truncation of the protein at Cys27 (c.80_81ins100 
p.Cys27*) (Fig. 14). 
 
 
The analysis of the cfDNA, however, did not detect any mutation of interest. 
 
Patient 2 
The analysis of the genomic DNA in this patient highlighted two pathogenic mutations. The first one 
is an insertion of a T between nucleotide 390 and 391, resulting in a stop codon and a truncated protein 
at Arg131 (c.390_391insT p.Arg131*). It has a VF of 7.2% and is classified as definitely pathogenic 
(5). 
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The second one is a missense mutation (T>A) at nucleotide 526 of the TP53 gene, resulting in the 
substitution of a cysteine with a serine (aminoacid 176), with a VF of 2.5% and a classification of 4 
(Fig. 15). 
 
 
 
The analysis of the cfDNA detected the mutation in the TP53 genes described also in genomic DNA 
but, interestingly, with a VF of 4.8% (Fig. 16). 
 
 
 
Patients 3, 4 and 5 
The analysis on both genomic and circulating DNA in these patients did not revealed the presence of 
somatic mutation in genes of the panel. 
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Patient 6 
The analysis of the genomic DNA in this patient highlighted two pathogenic mutations. The first one 
involved the BRCA2 gene and consist in the formation of a splice acceptor site due to the substitution 
of two A with one T at nucleotide 7436 (c.7436-2A>T). Its VF is of 13.7% and is classified as 5. 
The second one is a likely pathogenic (4),splice donor site in the TP53 gene, involving a deletion of 
nucleotides from 372 to 375 and an insertion of 2 G (c.372_375+2delinsG). The observed VF of this 
mutation is 14.1% (Fig. 17). 
 
As for patient 1, the analysis of the cfDNA does not detect any mutation. 
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DISCUSSION	AND	CONCLUSIONS	
 
The analysis of genetic alterations in tumours is becoming a routine in clinical practice due to the 
possibility to predict response to targeted-therapies or as prognostic markers, affecting progression-
free survival (PFS) and overall survival (OS) of many cancers. 
Nowadays, the golden standard in somatic alteration assessment is represented by tumour biopsy. This 
approach, however, have some limitations. First of all, it is an invasive approach that carries a high 
complications rate 247,248. Then, biopsies allow to analyse only a small fraction of the tumour lesion, 
with a high risk of considering just a snapshot of the highly heterogeneous cancer 249. It is often 
necessary to repeat sampling of the tumour tissue and this procedure, besides intrinsic risks described 
above, is often considered unethical or impossible in cases of irradiated tumours250. 
The discovery of DNA circulating in blood opened the way to a surrogate marker for tumour tissue 
biopsy, called ‘liquid biopsy’. Blood drawing is a minimally invasive procedure that can be repeated 
several times without causing deep complication for the patient, but at the same time can furnish 
information on early cancer detection251, analyse the evolution of genetic abnormalities and 
monitoring tumour dynamics252. 
Limitations on clinical application of cfDNA analysis are mainly related to the necessary development 
of novel, highly sensitive assays able to detect very low frequency mutations in small amounts of 
material with high sensitivity and specificity, to the lack of homogeneity on pre-analytical procedure 
between different studies and to procedure that validate cfDNA based assay in comparison with actual 
gold standard approaches. 
The first biomarker we can consider is the total amount of cfDNA. Several studies have pointed out 
that cancer-affected patients have higher levels of circulating DNA, compared with healthy subjects. 
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In non-small cells lung cancer (NSCLC) patients median concentration is eight time higher compared 
to heavy smokers controls, achieving a 75% sensitivity and 86% specificity in detecting NSCLC 253. 
cfDNA integrity has been evaluated as a diagnostic marker in colorectal cancers (CRC), periampullary 
cancers and BC. 
These two markers proved not to be widely applicable due to the inability to clearly discriminate 
between malignant and non malignant diseases such as chronic inflammatory disorders, thus having a 
high risk of false positive detection254. 
Genetic alterations can be highly specific biomarkers that allow discriminating between malignant and 
non-malignant conditions. Cancer-specific epigenetic modification, such as hypermethylation of 
regulatory genes, can be a powerful marker in different cancers. Promoter methylation of SEPT9 can 
help detecting CRC at early stages and a commercial test is under approval by Food and Drug 
Administration (FDA). Somatic mutations in oncogenes can be used as biomarkers to identify, 
evaluate prognosis and therapy and monitor cancer development255. 
In this work we have compared the detection of mutations in 16 genes (ATM , BARD1 , BRCA1 , 
BRCA2 , BRIP1 , CDK12 , CHEK1 , CHEK2 , FANCL , PALB2 , PPP2R2A , RAD51B , RAD51C , 
RAD51D , RAD54L , TP53) involved in homologous recombination (HR) in genomic, obtained from 
fresh tissue, and circulating DNA, obtained from plasma, in 6 patients affected by BC. 
We firstly validated the procedure to extract cfDNA from plasma, testing four different kits, two 
automated and two manuals, with starting plasma volumes ranging between 300 μl and 4 ml. In a 
second project, we also tested the difference in terms of cfDNA quality between the commonly used 
K3EDTA and the Blood STASIS 21-ccfDNA tubes, that contains an additive that prevents cells from 
lysis and preserve cfDNA from degradation for up to 21 days at room temperature. 
We conclude that, in order to obtain good amount of high quality cfDNA, the best procedure is to 
collect blood in the Blood STASIS 21-ccfDNA tubes, considering that it is not always possible to 
separate plasma within 1 h from venepuncture. 
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The extraction has to be performed starting from at least 3 ml of plasma, considering that the more 
plasma can be processed the more cfDNA can be collected and analysed, increasing dramatically the 
representativeness of the sample in particular in the presence of mutations with very low VF. 
We choose the QIAamp MinElute ccfDNA Midi Kit (Qiagen) because it allows us to scale the input 
plasma volume from 3 ml to 10 ml and it gives better yield in comparison with the other manual kit. 
We observe a great variability in the levels of cfDNA in different samples, according with the 
literature. 
We performed the target enrichment protocol following manufacturer instructions and all the samples 
passed the QC. 
No mutations have been detected in 3 out of 6 patients analysed (numbers 3, 4 and 5), either in 
genomic or circulating DNA. 
Mutations in at least one of genomic and circulating DNA have been identified in the other 3 patients. 
In two genomic samples we observe the presence of mutations. Surprisingly, no mutations have been 
detected in cfDNA obtained from these two patients. Looking at QC reports of the target enrichment 
procedure, we can exclude that this result is caused by unsuccessful preparation and sequencing of the 
libraries. One possible explanation of what we have observed can be associated to the proliferation 
rate of the tumour. Both patients 1 and 6 have, indeed, a Ki67 value of 20 at the diagnosis. The 
minimum Ki67 value indicating high proliferation rate is 25, suggesting these two patients have slow 
proliferating tumours. This fact can affect deeply the amount of cfDNA released in the circulation, 
resulting in a higher possibility to miss tumour-derived fragment among the physiological background 
cfDNA. To obtain a more representative view of the whole cfDNA composition that allows us to 
identify also mutation with low frequency, parallel analysis of different cfDNA aliquots or increased 
starting amount of sample must be considered. 
In addition to what already described, patient 6 harbours a splice acceptor mutation in the BCRA2 
gene. Patients enrolled in this project have been tested for mutation in BRCA 1/2 genes. This analysis 
is performed on whole blood, i.e. white blood cell DNA, and allows identifying germline mutations. 
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We enrolled only those patients with sporadic cancers, i.e. both BRCA 1 and BRCA 2 are wild type. 
We can thus conclude that the identified mutation is somatic, i.e. it is present only in the tumour tissue. 
In the patient 2, a mutation in TP53 is observed in both genomic and circulating DNA, while the 
second mutation affecting PALB2 is present only in the DNA extracted from the fresh tissue. 
Interestingly, TP53 mutation VF is higher in cfDNA compared to DNA obtained from the fresh tissue. 
A similar scenario has already been described in the literature and confirms that tissue biopsies are 
only representative of the fraction of material collected and do not detect tumour heterogeneity, while 
cfDNA can furnish information on the whole clones composing the tumour. 
Regarding the mutation in the PALB2 gene, the absence of the mutation in cfDNA can have different 
explanations. It is possible that the two mutations identified are associated with different clones, the 
one carrying the PALB2 having low proliferation rates, thus being undetectable as described in 
patients 1 and 6. By now, analytical procedures on cfDNA are not able to discriminate if mutations are 
harboured by the same clone or belong to different ones. Patient 2 has a Ki67 of 21, thus a low 
proliferation rate, but it is hard to determine if this value represent the contribution of just a clone or 
reflect the entire tumour proliferation, considering the limited sample analysed in the biopsy. 
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Future	perspectives	
In this study we identify mutations in a panel of 16 genes, associated with homologous recombination 
deficiency, in both circulating and fresh-tissue-extracted DNA. 
One limitation of this study is the reduced amount of patients analysed. We have by now 11 samples 
ready to be analysed and we are proceeding collecting samples of patients matching our inclusion 
criteria in order to increase the amount of data and this way have a better understanding of sensitivity 
and specificity of this method. 
Patients analysed will be monitored with further blood collection in order to verify the eventual 
occurrence of new mutations and data obtained will be crossed with the clinical data on disease status 
and development. 
Analysis of DNA extracted from patient’s white blood cells (WBC) will give us a deeper 
understanding of the germline mutational landscape in genes of the panel, allowing us to better assign 
the role of mutations observed during the analysis. 
The further identification of mutations clearly associated with approved therapies (PARPi and 
platinum salts) can direct the clinical management of the patient toward a more efficient and specific 
treatment of cancer. 
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